# Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI

> **NCT07138508** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 300 (actual)

## Conditions studied

- No Reflow Phenomenon
- Anterior STEMI

## Interventions

- **DRUG:** Nicorandil 20mg

## Key facts

- **NCT ID:** NCT07138508
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-10
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-03-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07138508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07138508, "Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07138508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*